A5048439038- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Melanoma and MAPK Pathways
- Connective Tissue Growth Factor Research
- Immunotherapy and Immune Responses
- Immune cells in cancer
- Nutrition, Genetics, and Disease
- Extracellular vesicles in disease
- Sarcoma Diagnosis and Treatment
- Dietary Effects on Health
- Diet and metabolism studies
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
- Biomarkers in Disease Mechanisms
- Cancer-related molecular mechanisms research
- Nanoplatforms for cancer theranostics
- MicroRNA in disease regulation
- Soft tissue tumor case studies
- melanin and skin pigmentation
- Monoclonal and Polyclonal Antibodies Research
- Synthesis and biological activity
- RNA modifications and cancer
- Cancer Mechanisms and Therapy
- Single-cell and spatial transcriptomics
Fondazione IRCCS Istituto Nazionale dei Tumori
2015-2025
University of Milan
2014
University of Milano-Bicocca
2014
Genomics (United Kingdom)
2014
Zimmer Biomet (United States)
2014
Melanoma Institute Australia
2009
University of Antwerp
2007
ZNA Middelheim Hospital
2007
The accrual of myeloid-derived suppressor cells (MDSCs) represents a major obstacle to effective immunotherapy in cancer patients, but the mechanisms underlying this process human setting remain elusive. Here, we describe set microRNAs (miR-146a, miR-155, miR-125b, miR-100, let-7e, miR-125a, miR-146b, miR-99b) that are associated with MDSCs and resistance treatment immune checkpoint inhibitors melanoma patients. miRs were identified by transcriptional analyses as being responsible for...
Abstract In tumor-bearing mice, cyclic fasting or fasting-mimicking diets (FMD) enhance the activity of antineoplastic treatments by modulating systemic metabolism and boosting antitumor immunity. Here we conducted a clinical trial to investigate safety biological effects cyclic, five-day FMD in combination with standard therapies. 101 patients, was safe, feasible, resulted consistent decrease blood glucose growth factor concentration, thus recapitulating metabolic changes that mediate...
// Elisabetta Vergani 1, * , Lorenza Di Guardo 2, Matteo Dugo 3, Sara Rigoletto 1 Gabrina Tragni 4 Roberta Ruggeri 5 Federica Perrone Elena Tamborini Annunziata Gloghini Flavio Arienti 6 Barbara 7 Paola Deho Loris De Cecco 3 Viviana Vallacchi Frati Eriomina Shahaj Antonello Villa Mario Santinami Filippo Braud 2 Licia Rivoltini Monica Rodolfo Immunotherapy Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy Medical...
PLX4032/vemurafenib is a first-in-class small-molecule BRAFV600E inhibitor with clinical activity in patients BRAF mutant melanoma. Nevertheless, drug resistance develops treated patients, and strategies to overcome primary acquired are required. To explore the molecular mechanisms involved PLX4032, we investigated its effects on cell proliferation signaling panel of 27 genetically characterized patient-derived melanoma lines. Cell sensitivity PLX4032 was dependent independent from other...
Clinical response to MAPK inhibitors in metastatic melanoma patients is heterogeneous for reasons still needing be elucidated. As the patient immune activity contributes treatment clinical benefit, pre-existing level of immunity at tumor site may provide biomarkers disease outcome therapy. Here we investigated whether assessing density and spatial tissue distribution key cells microenvironment could identify predisposed respond inhibitors.Pretreatment biopsies from a total 213 (158 training...
586 Background: Immune checkpoint blockade is a standard-of-care treatment for mRCC patients, but the immune mechanisms driving clinical benefit remain underexplored. In I-RENE trial (NCT04891055), we conducted comprehensive evaluation of myeloid-derived suppressor cell (MDSC) and lymphoid dynamics their impact on efficacy nivolumab. Methods: The study prospective, translational, real-world multicenter involving patients treated with nivolumab after failure previous VEGFR-targeted therapies....
Abstract The DHCR24 gene encoding for the 3β‐hydroxysterol Δ24‐reductase, an oxidoreductase involved in cholesterol biosynthesis, was isolated by subtractive hybridization as highly expressed a short‐term melanoma cell line derived from cutaneous metastases (S/M2) compared to that obtained autologous primary tumor (S/P). (alias seladin‐1, diminuto/dwarf1 homolog) has been reported act antiapoptotic factor neurons. Gene expression analysis Northern blot confirmed 5‐fold upregulated S/M2 S/P...
Abstract BRAFV600E is the most represented somatic point mutation in cutaneous melanoma, thus providing a unique molecular marker for this disease. The development of efficient methods its detection free circulating DNA patients may lead to improvement diagnostic and prognostic tools. With aim, we evaluated whether represents detectable plasma/serum from melanoma pilot study. Circulating cell‐free was extracted serum or plasma 15 healthy donors 41 at different clinical stages obtained either...
Abstract CCN3/nephroblastoma overexpressed belongs to the CCN family of genes that encode secreted proteins associated with extracellular matrix (ECM) and exert regulatory effects at cellular level. Overexpression CCN3 was shown in metastatic melanoma cells compared primary tumor from same patient. Analysis short-term cultures 50 melanomas revealed a heterogeneous expression pattern both 46-kDa full-length cytoplasmic/secreted protein 32-kDa nuclear-truncated form. The different patterns...
Durable remissions are observed in 10%–20% of treated patients with advanced metastatic melanoma but the factors associated long-term complete clinical responses largely unknown. Here, we report molecular characteristics tumor evolution during disease progression along a 9-year course patient disseminated who received different treatments, including trametinib, ipilimumab, radiation, vemurafenib, surgical debulking and second ipilimumab course, ultimately achieving remission. Longitudinal...
Plexins are transmembrane high-affinity receptors for semaphorins, regulating cell guidance, motility, and invasion. Functional evidences implicate semaphorin signals in cancer progression metastasis. Yet, it is largely unknown whether plexin genes genetically altered human tumors. We performed a comprehensive gene copy analysis mutational profiling of all nine members the family (plexinome), melanomas pancreatic ductal adenocarcinomas (PDACs), which characterized by high metastatic...
Sentinel lymph nodes set the stance of immune system to a localized tumor and are often first site be colonized by neoplastic cells that metastasize. To investigate how presence in sentinel may trigger pathways associated with metastatic progression, we analyzed transcriptional profiles archival node biopsy specimens obtained from melanoma patients. Biopsies positive were selected for comparable infiltration, or absence further regional metastases, relapse at 5-year follow-up. Unsupervised...
Targeted therapy with BRAF and MEK inhibitors has improved the survival of patients BRAF-mutated metastatic melanoma, but most relapse upon onset drug resistance induced by mechanisms including genetic epigenetic events. Among alterations, microRNA perturbation is associated development kinase inhibitor resistance. Here, we identified studied role miR-146a-5p dysregulation in melanoma resistance.The miR-146a-5p-regulated NFkB signaling network was drug-resistant cell lines tumor samples...